The annual biotech strategic meeting at the NYSE convenes a highly curated group of biotech executives, investors and drug development leaders to explore the most pressing strategic questions shaping the future of immuno-oncology.
The program will feature discussions on late-stage and commercial biotech strategy, emerging modalities such as in vivo cell therapies, AI-enabled drug development and the evolving global regulatory and financing landscape.
Designed to foster meaningful dialogue and high-value connections, this forum offers a unique opportunity to engage directly with leaders driving innovation and deal making across the biotech ecosystem.